Zymfentra (infliximab-dyyb)
Prior Authorization Request Form
Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

☐ **URGENT**

MEMBER INFORMATION	
LAST NAME:	**FIRST NAME:**
PHONE NUMBER:	**DATE OF BIRTH:**
STREET ADDRESS:	
CITY:	**STATE:** **ZIP CODE:**
PATIENT INSURANCE ID NUMBER:	

☐ **MALE** ☐ **FEMALE** **HEIGHT (IN/CM):** _____ **WEIGHT (LB/KG):** _____

ALLERGIES: _____

If you are not the patient or the prescriber, you will need to submit a PHI Disclosure Authorization form with this request which can be found at the following link: primetherapeutics.com/NOPP

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____

AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION	
LAST NAME:	**FIRST NAME:**
PRESCRIBER SPECIALTY:	**EMAIL ADDRESS:**
NPI NUMBER:	**DEA NUMBER:**
PHONE NUMBER:	**FAX NUMBER:**
STREET ADDRESS:	
CITY:	**STATE:** **ZIP CODE:**
REQUESTER (IF DIFFERENT THAN PRESCRIBER):	**OFFICE CONTACT PERSON:**

Continued next page

Zymfentra (infliximab-dyyb)
Prior Authorization Request Form
Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

MEDICATION OR MEDICAL DISPENSING INFORMATION

MEDICATION NAME:

DOSE/STRENGTH:	**FREQUENCY:**	**LENGTH OF THERAPY/REFILLS:**	**QUANTITY:**

☐ **NEW THERAPY** ☐ **RENEWAL** IF RENEWAL, DATE THERAPY INITIATED:

DURATION OF THERAPY (SPECIFIC DATES):

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION?
☐ **YES (IF YES, COMPLETE BELOW)** ☐ **NO**

Medication/Therapy (Specify Drug Name And Dosage):	**Duration Of Therapy (Specify Dates):**	**Response/Reason For Failure/Allergy:**

2. LIST DIAGNOSES:	**ICD-10:**
☐ **Ulcerative colitis(UC)** ☐ **Crohn's Disease(CD)** ☐ **Other diagnosis:** _____ ICD-10 CODE(S): _____	

3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.

Is patient going to be using drug in a clinical trial? ☐ **Yes** ☐ **No**

<u>Initial Request</u>:

Does patient have moderate-to-severe ulcerative colitis? ☐ **Yes** ☐ **No** **Please submit chart documentation.**

Does patient have Crohn's Disease? ☐ **Yes** ☐ **No**

Is prescriber a gastroenterologist? ☐ **Yes** ☐ **No**

Is prescriber a rheumatologist? ☐ **Yes** ☐ **No**

Is this request for subcutaneous maintenance therapy ONLY (NOT INDUCTION THERAPY- medical)?

☐ **Yes** ☐ **No**

Zymfentra (infliximab-dyyb)
Prior Authorization Request Form
Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

Has patient tried and failed at least one of the following three therapies: corticosteroids, azathioprine and/or 6-mercaptopurine? ☐ Yes ☐ No Please submit chart documentation.

Has patient tried and failed at least one of the following: glucocorticoid therapy or methotrexate or azathioprine or 6-mercaptopurine and/or 5-ASA/mesalamine? ☐ Yes ☐ No Please submit chart documentation.

Has patient tried and failed at least three months with the biosimilar for Humira, adalimumab-aacf product? ☐ Yes ☐ No Please submit chart documentation.

Does patient have an absolute contraindication to Humira or adalimumab-aacf? ☐ Yes ☐ No Please submit chart documentation.

Has the patient tried and had an inadequate response to a 4-month trial of the biosimilar for Stelara, Otulfi(usekinumab-aauz)? ☐ Yes ☐ No (Please submit documentation)

Does patient have a absolute contraindication to the biosimilar for Stelara, Otulfi(usekinumab-aauz)? ☐ Yes ☐ No (Please submit documentation)

Is patient currently being treated with another biologic response modifier or immunomodulatory agent? ☐ Yes ☐ No

If so, will that biologic response modifier or immunomodulatory agent be discontinued when Zymfentra(infliximab-dyyb) is started? ☐ Yes ☐ No

Renewal Request:

Is patient continuing to demonstrate a positive clincial response? ☐ Yes ☐ No Please submit chart documentation.

Is prescriber a gastroenterologist? ☐ Yes ☐ No

Is prescriber a rheumatologist? ☐ Yes ☐ No

Will the patient use drug in combination with another biologic response modifier or immunomodulatory agent? ☐ Yes ☐ No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

Zymfentra (infliximab-dyyb)
Prior Authorization Request Form
Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ Date: _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640
MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program
Attn: CP-4201
P.O. Box 64811
St. Paul, MN 55164-0811
Phone: 877-228-7909